| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | UNC0638 | CTRPv2 | pan-cancer | AAC | 0.06 | 0.1 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.1 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.1 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.1 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.083 | 0.1 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.051 | 0.1 |
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | -0.054 | 0.1 |